Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial

Abstract Background Detecting epidermal growth factor receptor (EGFR) activating mutations in plasma could guide EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment for advanced non-small cell lung cancer (NSCLC). However, dynamic quantitative changes of plasma EGFR mutations during the whole course...

Full description

Bibliographic Details
Main Authors: Qing Zhou, Jin-Ji Yang, Zhi-Hong Chen, Xu-Chao Zhang, Hong-Hong Yan, Chong-Rui Xu, Jian Su, Hua-Jun Chen, Hai-Yan Tu, Wen-Zhao Zhong, Xue-Ning Yang, Yi-Long Wu
Format: Article
Language:English
Published: BMC 2016-09-01
Series:Journal of Hematology & Oncology
Subjects:
Lung cancer
Plasma EGFR mutation
Quantitative change
Circulating free DNA
EGFR-TKI
Online Access:http://link.springer.com/article/10.1186/s13045-016-0316-8

Internet

http://link.springer.com/article/10.1186/s13045-016-0316-8

Similar Items